Witnessing the stock’s movement on the chart, on Wednesday, Brainstorm Cell Therapeutics, Inc (NASDAQ: BCLI) had a quiet start as it plunged -4.84% to $1.18, before settling in for the price of $1.24 at the close. Taking a more long-term approach, BCLI posted a 52-week range of $0.72-$10.05.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 0.00%. Meanwhile, its Annual Earning per share during the time was 32.00%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 30.74%. This publicly-traded company’s shares outstanding now amounts to $7.91 million, simultaneously with a float of $6.17 million. The organization now has a market capitalization sitting at $9.37 million. At the time of writing, stock’s 50-day Moving Average stood at $1.1943, while the 200-day Moving Average is $2.1792.
Brainstorm Cell Therapeutics, Inc (BCLI) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Brainstorm Cell Therapeutics, Inc’s current insider ownership accounts for 22.32%, in contrast to 12.88% institutional ownership. According to the most recent insider trade that took place on Oct 01 ’24, this organization’s President & CEO bought 1,836 shares at the rate of 3.43, making the entire transaction reach 6,292 in total value, affecting insider ownership by 80,960. Preceding that transaction, on Sep 30 ’24, Company’s President & CEO bought 22,000 for 0.23, making the whole transaction’s value amount to 5,016. This particular insider is now the holder of 1,186,865 in total.
Brainstorm Cell Therapeutics, Inc (BCLI) Earnings and Revenue Records
Brainstorm Cell Therapeutics, Inc’s EPS increase for this current 12-month fiscal period is 30.74% and is forecasted to reach -0.93 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 29.48% through the next 5 years, which can be compared against the 32.00% growth it accomplished over the previous five years trading on the market.
Brainstorm Cell Therapeutics, Inc (NASDAQ: BCLI) Trading Performance Indicators
Let’s observe the current performance indicators for Brainstorm Cell Therapeutics, Inc (BCLI). It’s Quick Ratio in the last reported quarter now stands at 0.21. The Stock has managed to achieve an average true range (ATR) of 0.17.
In the same vein, BCLI’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.98, a figure that is expected to reach -0.33 in the next quarter, and analysts are predicting that it will be -0.93 at the market close of one year from today.
Technical Analysis of Brainstorm Cell Therapeutics, Inc (BCLI)
Going through the that latest performance of [Brainstorm Cell Therapeutics, Inc, BCLI]. Its last 5-days volume of 12.51 million indicated improvement to the volume of 0.78 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 19.46% While, its Average True Range was 0.1930.
Raw Stochastic average of Brainstorm Cell Therapeutics, Inc (BCLI) in the period of the previous 100 days is set at 25.70%, which indicates a major rise in contrast to 9.70% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 89.00% that was lower than 93.54% volatility it exhibited in the past 100-days period.
